Phase II study of cisplatin and dacarbazine for metastatic colorectal carcinoma resistant to 5-fluorouracil

Oncology

Volumn 56, Issue 4, 1999, Pages 297-300

  Içli, Fikri ^a   Arican, Ali ^b   Çay, Filiz ^a   Akbulut, Hakan ^a   Dinçol, Dilek ^a   Karaoǧuz, Handan ^a   Demirkazik, Ahmet ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

5 Fluorouracil; Chemotherapy; Cisplatin; Colorectal carcinoma; Dacarbazine

Indexed keywords

CISPLATIN; DACARBAZINE; FLUOROURACIL; LEVAMISOLE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CARCINOMA; FEMALE; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COLORECTAL NEOPLASMS; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 0344848672     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011981     Document Type: Article

References (8)

1. Petrelli N, Rustum YM: Fluorouracil and leucovorin: There is a choice. J Clin Oncol 1993; 11:382-383.
2. Poon MA, O'Connell MJ, Wiehand HS, Krosk JE, Gerstner JB, Tschetter LK, Levitt R, Kardinol JG, Maillard JA: Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9:1967-1972.
3. Rothenberg ML, Eckhardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ, Von Hoff DO: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-1135.
4. Fletcher WS, Green S, Fletcher JR, Dana B, Jewell W, Townsend RA: Evaluation of cis-platinum and DTIC combination chemotherapy in disseminated melanoma. A Southwest Oncology Group Study. Am J Clin Oncol 1988; 11:589-593.
5. Cunningham D, Pyrhönen S, James RD, Punt CJA, Hickish TS, Heikkila R, Johannesen T, Starkhammer H, Topham CA, Ong E, Herait P, Jacques C: A phase III multicenter randomized study of CTP-11 versus supportive care alone in patients with 5FU-resistant metastatic colorectal cancer (abstract 1). ASCO Proceedings p:1a 1998.
6. Cassano A, Pozzo C, Corsi DC, Fontana T, Noviella MR, Astone A, Barone C: Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. J Cancer Res Clin Oncol 1995;121:474-477.
7. Tsavaris N, Tentas K, Bacoyiannis C, Katsikas M, Jakelaropoulos N, Kosmas C, Daliani D, Kosmidis P: 5-Fluorouracil, folinic acid and cisplatin in advanced colorectal cancer: A pilot study. Anticancer Drugs 1995;6:599-603.
8. Ahlgren JD, Trocki O, Gullo JJ, Goldberg R, Muir WA, Sisk R, Schacter L: Protracted infusion of 5-FU with weekly low-dose cisplatin as second-line therapy in patients with metastatic colorectal cancer who failed 5-FU monotherapy. Cancer Invest 1991;9:27-33.